Other
Change in AR
Neurocrine Biosciences Change in AR decreased by 38.5% to $81.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 120.6%, from $36.90M to $81.40M. Over 3 years (FY 2021 to FY 2024), Change in AR shows an upward trend with a 13.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2015
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase in accounts receivable relative to sales may signal slower collections or credit risk, while a decrease suggests efficient cash conversion.
Detailed definition
This measures the net change in the amount owed to the company by customers for goods or services delivered on credit. I...
Peer comparison
Standard working capital metric used to evaluate credit and collection cycles.
Metric ID:
anet_change_in_accounts_receivableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.70M | $5.30M | $21.70M | $78.00M | $15.50M | $22.20M | $46.50M | $41.70M | $0.00 | $30.40M | $21.40M | $11.30M | $17.60M | $12.90M | $0.00 | $36.90M | $79.70M | $132.30M | $81.40M |
| QoQ Change | — | -50.5% | +309.4% | +259.4% | -80.1% | +43.2% | +109.5% | -10.3% | -100.0% | — | -29.6% | -47.2% | +55.8% | -26.7% | -100.0% | — | +116.0% | +66.0% | -38.5% |
| YoY Change | — | — | — | — | +44.9% | +318.9% | +114.3% | -46.5% | -100.0% | +36.9% | -54.0% | -72.9% | — | -57.6% | -100.0% | +226.5% | +352.8% | +925.6% | +120.6% |
Range$0.00 – $132.30M
CAGR+57.0%
Avg YoY Growth+122.1%
Median YoY Growth+40.9%
Change in AR at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's change in ar?
- Neurocrine Biosciences (NBIX) reported change in ar of $81.40M in Q1 2026.
- How has Neurocrine Biosciences's change in ar changed year-over-year?
- Neurocrine Biosciences's change in ar increased by 120.6% year-over-year, from $36.90M to $81.40M.
- What is the long-term trend for Neurocrine Biosciences's change in ar?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's change in ar has grown at a 13.8% compound annual growth rate (CAGR), from $28.40M to $41.80M.
- What does change in ar mean?
- The change in the balance of money owed to the company by its customers.